Gonadotropin-regulated lymphangiogenesis in ovarian cancer is mediated by LEDGF-induced expression of VEGF-C

Cancer Research

Volumn 69, Issue 24, 2009, Pages 9306-9314

  Sapoznik, Stav ^a   Cohen, Batya ^a   Tzuman, Yael ^a   Meir, Gila ^a   Ben Dor, Shifra ^a   Harmelin, Alon ^a   Neeman, Michal ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CETRORELIX; ESTROGEN; FOLLITROPIN; GONADOTROPIN; LENS EPITHELIUM DERIVED GROWTH FACTOR; LUTEINIZING HORMONE; MESSENGER RNA; PROTEIN P75; SMALL INTERFERING RNA; VASCULOTROPIN C;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER RISK; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DISEASE SEVERITY; DNA RESPONSIVE ELEMENT; ESTROGEN RELEASE; FEMALE; FOLLITROPIN RELEASE; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC CONSERVATION; HORMONAL REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEDGF GENE; LUTEINIZING HORMONE RELEASE; LYMPHANGIOGENESIS; MENOPAUSE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARIECTOMY; OVARY CARCINOMA; OVARY INSUFFICIENCY; P75 GENE; POSTMENOPAUSE; PRIORITY JOURNAL; PROMOTER REGION; STRESS RESPONSE ELEMENT; TUMOR XENOGRAFT; VEGF C GENE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL LINE, TUMOR; FEMALE; FOLLICLE STIMULATING HORMONE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUTEINIZING HORMONE; LYMPHATIC VESSELS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; OVARIECTOMY; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 73649129634     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-1213     Document Type: Article

References (44)

1. Mandai M, Konishi I, Kuroda H, Fujii S. LH/hCG action and development of ovarian cancer-a short review on biological and clinical/epidemiological aspects. Mol Cell Endocrinol 2007;269:61-4.
2. Parrott JA, Doraiswamy V, Kim G, Mosher R, Skinner MK. Expression and actions of both the follicle stimulating hormone receptor and the luteinizing hormone receptor in normal ovarian surface epithelium and ovarian cancer. Mol Cell Endocrinol 2001;172: 213-22.
3. Syed V, Ulinski G, Mok SC, Yiu GK, Ho SM. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 2001; 61:6768-76.
4. Lukanova A, Kaaks R. Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiol Biomarkers Prev 2005;14:98-107.
5. Choi JH, Choi KC, Auersperg N, Leung PC. Gonadotropins activate proteolysis and increase invasion through protein kinase A and phosphatidylinositol 3-kinase pathways in human epithelial ovarian cancer cells. Cancer Res 2006;66:3912-20.
6. Konishi I. Gonadotropins and ovarian carcinogenesis: a new era of basic research and its clinical implications. Int J Gynecol Cancer 2006;16:16-22.
7. Schiffenbauer YS, Abramovitch R, Meir G, et al. Loss of ovarian function promotes angiogenesis in human ovarian carcinoma. Proc Natl Acad Sci U S A 1997;94: 13203-8.
8. Thomas CM, Boss EA, Boonstra H, van Tienoven D, Sweep CG, Massuger LF. Gonadotropins and female sex steroid hormones in cyst fluid and serum from patients with ovarian tumors. Eur J Gynaecol Oncol 2008; 29:468-72.
9. Van Trappen PO, Pepper MS. Lymphangiogenesis in human gynaecological cancers. Angiogenesis 2005;8: 137-45.
10. 18F-FDG-PET/CT: an unusual finding. Cancer Imaging 2006;6:20-3.
11. 18F-FDG PET/CT in a patient with lymph node metastasis from ovarian adenocarcinoma. AJR Am J Roentgenol 2006;187:W285-9.
12. Sangoi AR, McKenney JK, Dadras SS, Longacre TA. Lymphatic vascular invasion in ovarian serous tumors of low malignant potential with stromal microinvasion: a case control study. Am J Surg Pathol 2008;32:261-8.
13. Sundar SS, Zhang H, Brown P, et al. Role of lymphangiogenesis in epithelial ovarian cancer. Br J Cancer 2006; 94:1650-7.
14. Schoppmann SF, Horvat R, Birner P. Lymphatic vessels and lymphangiogenesis in female cancer: mechanisms, clinical impact and possible implications for anti-lymphangiogenic therapies [review]. Oncol Rep 2002;9:455-60.
15. Su JL, Yang PC, Shih JY, et al. The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell 2006;9:209-23.
16. Ueda M, Hung YC, Terai Y, et al. Vascular endothelial growth factor-C expression and invasive phenotype in ovarian carcinomas. Clin Cancer Res 2005;11:3225-32.
17. Burton JB, Priceman SJ, Sung JL, et al. Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res 2008;68:7828-37.
18. Shibata MA, Morimoto J, Shibata E, Otsuki Y. Combination therapy with short interfering RNA vectors against VEGF-C and VEGF-A suppresses lymph node and lung metastasis in a mouse immunocompetent mammary cancer model. Cancer Gene Ther 2008;15: 776-86.
19. Chen Z, Varney ML, Backora MW, et al. Downregulation of vascular endothelial cell growth factor-C expression using small interfering RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances survival. Cancer Res 2005;65:9004-11.
20. + macrophages in advanced ovarian cancer. Cancer Res 2008;68:1100-9.
21. Cohen B, Addadi Y, Sapoznik S, et al. Transcriptional regulation of vascular endothelial growth factor c by oxidative and thermal stress is mediated by lens epitheliumderived growth factor/p75. Neoplasia 2009;11:921-33.
22. Nguyen TA, Boyle DL, Wagner LM, Shinohara T, Takemoto DJ. LEDGF activation of PKCγ and gap junction disassembly in lens epithelial cells. Exp Eye Res 2003;76:565-72.
23. Shinohara T, Singh DP, Fatma N. LEDGF, a survival factor, activates stress-related genes. Prog Retin Eye Res 2002;21:341-58.
24. Wu X, Daniels T, Molinaro C, Lilly MB, Casiano CA. Caspase cleavage of the nuclear autoantigen LEDGF/p75 abrogates its pro-survival function: implications for autoimmunity in atopic disorders. Cell Death Differ 2002;9:915-25.
25. Fatma N, Singh DP, Shinohara T, Chylack LT, Jr. Transcriptional regulation of the antioxidant protein 2 gene, a thiol-specific antioxidant, by lens epithelium-derived growth factor to protect cells from oxidative stress. J Biol Chem 2001;276:48899-907.
26. Singh DP, Fatma N, Kimura A, Chylack LT, Jr., Shinohara T. LEDGF binds to heat shock and stress-related element to activate the expression of stress-related genes. Biochem Biophys Res Commun 2001;283:943-55.
27. Singh DP, Kubo E, Takamura Y, et al. DNA binding domains and nuclear localization signal of LEDGF: contribution of two helix-turn-helix (HTH)-like domains and a stretch of 58 amino acids of the N-terminal to the trans-activation potential of LEDGF. J Mol Biol 2006;355:379-94.
28. Shin JH, Piao CS, Lim CM, Lee JK. LEDGF binding to stress response element increases αB-crystallin expression in astrocytes with oxidative stress. Neurosci Lett 2008;435:131-6.
29. Maertens GN, Cherepanov P, Engelman A. Transcriptional co-activator p75 binds and tethers theMyc-interacting protein JPO2 to chromatin. J Cell Sci 2006;119:2563-71.
30. Turlure F, Maertens G, Rahman S, Cherepanov P, Engelman A. A tripartite DNA-binding element, comprised of the nuclear localization signal and two AT-hook motifs, mediates the association of LEDGF/p75 with chromatin in vivo. Nucleic Acids Res 2006;34:1653-75.
31. Daugaard M, Kirkegaard-Sorensen T, Ostenfeld MS, et al. Lens epithelium-derived growth factor is an Hsp70-2 regulated guardian of lysosomal stability in human cancer. Cancer Res 2007;67:2559-67.
32. Huang TS, Myklebust LM, Kjarland E, et al. LEDGF/ p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro. Mol Cancer 2007;6:31.
33. Dorward AM, Shultz KL, Beamer WG. LH analog and dietary isoflavones support ovarian granulosa cell tumor development in a spontaneous mouse model. Endocr Relat Cancer 2007;14:369-79.
34. v-integrin. Gynecol Oncol 2002;84:296-302.
35. Tian X, Cong M, Zhou W, Zhu J, Liu Q. Relationship between protein expression of VEGF-C, MMP-2 and lymph node metastasis in papillary thyroid cancer. J Int Med Res 2008;36:699-703.
36. Boone B, Blokx W, De Bacquer D, Lambert J, Ruiter D, Brochez L. The role of VEGF-C staining in predicting regional metastasis in melanoma. Virchows Arch 2008; 453:257-65.
37. Mattila MM, Ruohola JK, Karpanen T, Jackson DG, Alitalo K, Harkonen PL. VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors. Int J Cancer 2002;98:946-51.
38. Karpanen T, Egeblad M, Karkkainen MJ, et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 2001;61:1786-90.
39. Hoshida T, Isaka N, Hagendoorn J, et al. Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. Cancer Res 2006;66:8065-75.
40. Mandriota SJ, Jussila L, Jeltsch M, et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 2001;20: 672-82.
41. Meirow D, Assad G, Dor J, Rabinovici J. The GnRH antagonist cetrorelix reduces cyclophosphamideinduced ovarian follicular destruction in mice. Hum Reprod 2004;19:1294-9.
42. Arencibia JM, Bajo AM, Schally AV, Krupa M, Chatzistamou I, Nagy A. Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207. Anticancer Drugs 2002;13:949-56.
43. Yokoyama A, Cleary ML. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell 2008;14:36-46.
44. Daniels T, Zhang J, Gutierrez I, et al. Antinuclear autoantibodies in prostate cancer: immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis. Prostate 2005; 62:14-26.